APLM

About Apollomics Inc. Class A Ordinary Shares (APLM) Stock

Apollomics Inc. Class A Ordinary Shares (APLM) closed the 2026-09-17 session at $22.52, up 1.90% versus the previous close (+0.42). The stock opened at $23.00 and traded between $22.52 and $25.00 during that session. Session trading volume was 3K shares. The volume-weighted average price (VWAP) is $23.03.

Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia. Company has three new immuno-oncology product candidates: APL-501, APL-502 and APL-801 include mono-specific and bi-specific antibodies to fight against cancer.

Apollomics Inc. Class A Ordinary Shares has a market capitalization of $65.7 million. APLM is listed on the XNAS exchange. The company employs approximately 15 people. The recorded listing date is 2023-03-30.

On this page you can find market APLM stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.

Explore more: View today's market movers, use the stock screener, or browse all sectors.